In controlled studies of sitagliptin (as monotherapy and combination therapy), overall incidence of adverse reactions/discontinuation similar to placebo
Most commonly reported adverse reactions include nasopharyngitis, URI, HA
Postmarketing surveillance found association with sitagliptin and development of acute pancreatitis
Confounding variables such as diabetes, hypercholesterolemia, hypertriglyceridemia, obesity
Also postmarketing reports of serious allergic reactions (including anaphylactoid reactions, angioedema, SJS)
Studies of other drugs in this class additionally report lymphopenia, cough, peripheral edema, transaminitis, and hypertension.
Other side effects reported in patients taking this class of medication include joint pain
Confounding variables such as diabetes, hypercholesterolemia, hypertriglyceridemia, obesity
DPP-4 inhibitors
GLP-1 agonists
Proton-pump inhibitor
ACE inhibitor
SGLT-2 Inhibitor
Angiotensin II receptor antagonists
Calcium channel blockers
Aminoglycosides